Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Dabigatran-induced esophagitis: A frequently overlooked adverse effect
Atrial fibrillation (AF) is known to increase the risk of ischemic stroke and other thromboembolic events in patients with atrial fibrillation. For a long time, warfarin was the only available oral anticoagulant. Conventionally it was considered effective and widely prescribed for the prevention of thromboembolic events in patients with AF. However, routine laboratory monitoring on international normalized ratio (INR) and inevitable dose adjustments, potential interactions with several drugs and food presented significant inconvenience and challenge in managing patients taking warfarin on daily medical practice [1].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Nixiao Zhang, Xiushi Suzy Liu, Guangping Li, Tong Liu Tags: Correspondence Source Type: research
Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus
Atrial fibrillation increases the risk of ischemic stroke 4–5 fold [1] and doubles the mortality independently of other vascular risk factors [2]. The vast majority (>90%) of thrombi associated with atrial fibrillation originate from the left atrial appendage [3]. The direct factor Xa inhibitor apixaban is superior to warfarin in terms of stroke prevention with a lower risk of bleeding and mortality [4].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Ashkan Eftekhari, Dorte Damgaard, Erik L. Grove Tags: Correspondence Source Type: research
Cystatin C and risk of atrial fibrillation in elderly hypertensive patients without chronic kidney disease
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, associated with increased risk of stroke, heart failure, and mortality [1]. Epidemiological evidence indicates that there is increased risk of AF in patients with chronic kidney disease (CKD) [2–4], while CKD is an independent risk factor for the development of AF [5–7]. Cystatin C (Cys-C) is a low molecular weight protein secreted by all nucleated cells at a constant rate. Cys-C can be freely filtrated through the glomerulus, and is almost completely reabsorbed and degraded in the proximal tubules [8].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Wenqian Wang, Ruyu Yuan, Panagiotis Korantzopoulos, Gang Xu, Xudan Cui, Guangping Li, Tong Liu Source Type: research
Defensive medicine due to different fears by patients and physicians in geriatric atrial fibrillation patients and second victim syndrome
The treatment of atrial fibrillation (AF) patients has altered dramatically in recent years with the emergence and approval of the novel oral anticoagulants, antiplatelet or devices [1–4]; but under-treatment and under-education of AF patients continue [5] despite their high risk of stroke and clear indication for anticoagulation according to established risk scores [6,7]. Appropriate use and continued adherence are absolutely critical concerns. In a 1-year study of elderly patients with AF, 26% of patients 80years and older stopped taking oral anticoagulant drug within the first year, largely due to perceived safety issues.
Source: International Journal of Cardiology - March 22, 2016 Category: Cardiology Authors: Ozcan Ozeke, Sevgi Aras, Kazim Baser, Fatih Sen, Ozgur Kirbas, Serkan Cay, Firat Ozcan, Serkan Topaloglu, Dursun Aras, Sinan Aydogdu Source Type: research
Another side effect of ticagrelor: Atrial fibrillation
Ticagrelor, a novel direct and reversible P2Y12 receptor antagonist, was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) as demonstrated in the PLATO trial [1]. In addition, the recent PEGASUS-TIMI 54 trial also suggested that ticagrelor significantly decreased the risk of cardiovascular death, myocardial infarction or stroke in patients with prior myocardial infarction during a 33-month follow-up [2]. However, several adverse effects have been observed during the treatment with ticagrelor, such as bradyarrhythmias including sinus node pause and atrioventricular b...
Source: International Journal of Cardiology - March 21, 2016 Category: Cardiology Authors: Nixiao Zhang, Kang-Yin Chen, Jianping Zhao, Gang Xu, Guangping Li, Tong Liu Tags: Correspondence Source Type: research
Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States
The objective of this real-life study was to compare medication adherence to newly-initiated rivaroxaban or dabigatran therapy among NVAF patients in the United States (US).
Source: International Journal of Cardiology - March 17, 2016 Category: Cardiology Authors: Craig I. Coleman, Muralikrishna Tangirala, Thomas Evers Tags: Correspondence Source Type: research
Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy
Left atrial (LA) enlargement evaluated by echocardiography is a very strong predictor of cardiovascular (CV) outcomes such as atrial fibrillation (AF), stroke, congestive heart failure, and CV death in multiple clinical settings [1,2]. As a consequence, researchers have focused their attention on the best method to assess LA size. Left atrium is a thin-walled cardiac chamber directly exposed to left ventricular (LV) pressure during diastole, which represents its afterload. In particular, in hypertrophic cardiomyopathy (HCM), almost all patients have some degree of LV diastolic dysfunction.
Source: International Journal of Cardiology - March 16, 2016 Category: Cardiology Authors: Alessandra Giamundo, Grazia Canciello, Antonio Rapacciuolo, Francesca Musella, Gianluigi Savarese, Teresa Strisciuglio, Eugenio Stabile, Raffaele Izzo, Bruno Trimarco, Maria Angela Losi Source Type: research
Energy metabolic alterations in the progression of atrial fibrillation: Potential role of AMP-activated protein kinase as a critical regulator
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia associated with increased risk of heart failure and stroke [1]. Accumulating studies have revealed that a series of striking alterations in atrial electrical, structural, and autonomic properties is critical to most acquired forms of AF [2–3]. However, the impact of cardiac energy metabolism upon the initiation or persistence of AF is incompletely understood. Metabolomic and proteomic analyses have indicated a close relationship between metabolic dysfunction and AF development [4].
Source: International Journal of Cardiology - March 14, 2016 Category: Cardiology Authors: Jie Qiu, Shenghua Zhou, Qiming Liu Tags: Correspondence Source Type: research
Predictive value of circulating fibroblast growth factor-23 on atrial fibrillation: A Meta-analysis
Atrial fibrillation, which can result in stroke and thromboembolism in an approximately 5-fold increased risk, has been a growing burden to health care system with the aging of the population [1,2]. Traditional risk factors for AF have been attributed primarily to hypertension [3], coronary artery disease, heart failure [4,5], valvular heart disease, diabetes mellitus [6,7] and chronic kidney disease [8,9]. However, those risk factors only partly explain the incident and prevalent atrial fibrillation, further identification of novel, modifiable risk factors is eagerly pursued.
Source: International Journal of Cardiology - February 18, 2016 Category: Cardiology Authors: Lei Meng, Yajuan Yang, Zhiwei Zhang, Guangping Li, Tong Liu Source Type: research
Comparative effectiveness and safety of non-vitamin K Antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease
Non-vitamin K antagonist oral anticoagulants (NOACs) are approved for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). These agents are as effective as warfarin and are associated with less intracranial bleeding and may be preferable for many patients with NVAF [1]. However, the term non-valvular AF remains a source of confusion because clinical trials and guidelines have adopted variable definitions.
Source: International Journal of Cardiology - February 2, 2016 Category: Cardiology Authors: Peter A. Noseworthy, Xiaoxi Yao, Nilay D. Shah, Bernard J. Gersh Source Type: research
Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation
The risk of ischemic stroke, systemic thromboembolism, and all-cause death among heart failure patients previously diagnosed with diabetes mellitus is poorly described. We evaluated the risk of these endpoints among heart failure patients without diagnosed atrial fibrillation according to the presence of diabetes mellitus.
Source: International Journal of Cardiology - February 2, 2016 Category: Cardiology Authors: Line Melgaard, Anders Gorst-Rasmussen, Peter Søgaard, Lars Hvilsted Rasmussen, Gregory Y.H. Lip, Torben Bjerregaard Larsen Source Type: research
Novel composite score to predict atrial Fibrillation in acute stroke patients
The objective of the present study was to construct a model that can predict the presence of atrial fibrillation in ischemic stroke patients and to validate the model.
Source: International Journal of Cardiology - February 2, 2016 Category: Cardiology Authors: Woo-Keun Seo, Sung-Hoon Kang, Jin-Man Jung, Jeong-Yoon Choi, Kyungmi Oh Source Type: research
Impact of Chronic Kidney Disease on Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Atrial Fibrillation
Left atrial appendage occlusion (LAAO) using the Amplatzer cardiac plug (ACP) is preventive treatment of atrial fibrillation related thromboembolism.
Source: International Journal of Cardiology - January 8, 2016 Category: Cardiology Authors: Joelle Kefer, Apostolos Tzikas, Xavier Freixa, Samera Shakir, Sameer Gafoor, Jens Erik Nielsen-Kudsk, Sergio Berti, Gennaro Santoro, Adel Aminian, Ulf Landmesser, Fabian Nietlispach, Reda Ibrahim, Paolo Luciano Danna, Edouard Benit, Werner Budts, Francis Source Type: research
Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings
Large randomized controlled trials have found that in non-valvular atrial fibrillation (AF), non-vitamin K antagonist oral anticoagulants (NOACs) had a favorable risk–benefit profile, with significant reductions in stroke, mortality and intracranial hemorrhage, but possibly increased gastrointestinal bleeding [1]. After the approval of dabigatran, many agencies in different countries received reports of severe dabigatran related bleeding reports through their adverse event reporting system. Concurrently, several case reports of dabigatran induced bleeding were published in medical journals and discussed in the mainstream media.
Source: International Journal of Cardiology - January 6, 2016 Category: Cardiology Authors: Walid Darwiche, Theodora Bejan-Angoulvant, François Dievart, Dominique Babuty, Denis Angoulvant, Laurent Fauchier Tags: Correspondence Source Type: research
Effects of probucol on left atrial remodeling in patients with paroxysmal atrial fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and increases the risk of stroke and death. An increasing body of evidence indicate the role of inflammation and oxidative stress in the development and perpetuation of AF. Indeed, inflammation and oxidative stress are involved in electrophysiological and structural remodeling of the atria [1–3]. Probucol is a lipid-lowering drug that has potent antioxidant effects. Specifically, it attenuates the production of oxygen free radicals and also acts as a direct superoxide anion scavenger [4].
Source: International Journal of Cardiology - January 5, 2016 Category: Cardiology Authors: Qingmiao Shao, Panagiotis Korantzopoulos, Huaying Fu, Lan Ye, Enzhao Liu, Gang Xu, Guangping Li, Tong Liu Source Type: research
